The FDA has approved three new targeted therapies for different stages of advanced prostate cancer: Truqap for PTEN-deficient tumors, rucaparib for BRCA-mutated castration-resistant disease, and Akeega for BRCA2-mutated castration-sensitive cancer.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07650240 |
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07406282 |
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics |
RECRUITING | |
| NCT07213674 |
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer |
RECRUITING | PHASE3 |
| NCT07198633 |
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07005154 |
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer |
RECRUITING | PHASE2 |
| NCT06632977 |
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial |
RECRUITING | PHASE2 |
| NCT06421935 |
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06136650 |
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) |
RECRUITING | PHASE3 |
| NCT06136624 |
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) |
RECRUITING | PHASE3 |
| NCT06120491 |
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents |
ACTIVE_NOT_RECRUITING | PHASE3 |
